Clinical Trials

The purpose of this study is to learn more about bullous pemphigoid disease testings called BP180 and BP230 in patients without a clinical diagnosis of bullous pemphigoid. 

The purpose of this two-part study is to confirm the dose of nomacopan for Part A and sample size for Part B, and also rank the order of secondary endpoints for Part B, to evaluate the safety of nomacopan with adjunct OCS in Parts A and B, to test drug effectiveness and particularly whether treatment with nomacopan and adjunct oral corticosteroid (OCS), with steroid tapered (between weeks 2 and 24) according to disease response, leads to a higher proportion of patients in complete disease remission than treatment with placebo and adjunct OCS, and to examine whether there is a reduction in cumulative OCS use and ...

The primary purpose of this study is to demonstrate that Dupilumab is superior to placebo in achieving sustained remission off oral corticosteroids (OCS) in patients with bullous pemphigoid (BP). 

Recently, Interleukin (IL)-17 has been identified as a key driver of chronic inflammation in Bullous Pemphigoid (BP). Ixekizumab is a recombinant high-affinity fully human monoclonal antibody that targets IL-17A Immunoglobulin gamma-1 (IgG1)/kappa-class. The purpose of this study is to determine the effect of Ixekizumab on BP patients.

The primary objective of this study is to determine whether administration of FCX-007 in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Recessive Dystrophic Epidermolysis Bullosa (RDEB) and confirmed mutation of the type VII collagen gene (COL7A1) gene.

The purpose of this study is to learn more about Lewy Body disease and a skin condition called Bullous Pemphigoid.